Novartis Pharma AG: Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for ...

Akzo Nobel N.V.: AkzoNobel and Axalta Coating Systems Ltd. to Combine in All-Stock Merger of Equals, Creating a Premier Global Coatings Company

Creates a global coatings leader with $17 billion in revenue and an enterprise value of $25 billionSignificant value creation with approximately $600 million in cost synergies supporting strategic and ...

NIO: Cheap Entering FQ3'25 - Outsized FY2026 Growth Prospects

NIO reports strong October 2025 EV deliveries and projects a record Q4, signaling high demand despite competition. Click for ...
Novartis

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

Entering a catalyst-rich period, Novartis expects 15+ potentially submission-enabling readouts over the next two years. With significant replacement power and a robust pipeline featuring 30+ potential ...
Psychology Today

How Your Goals and Purpose Change Over Your Lifetime

As we move through our lives, our sense of purpose and goals naturally change. Here's what to expect and how to become the ...

I3 Verticals outlines 8–10% recurring revenue growth for 2026 while advancing SaaS expansion

Q4 2025 Management View CEO Gregory Daily reflected on the company's transformation, stating that "divesting our Merchant Services and our health care revenue cycle management businesses have turned a ...